Background {#Sec1}
==========

Elderly patients constitute the largest age group among all individuals with chronic kidney disease (CKD). The elderly are affected by the same types of kidney diseases as younger individuals, but their clinical course and morphological manifestation may be influenced by aging. Senescence is associated with an eGFR decline by approximately 0.8--1.7 ml/min per year, which limits renal function reserve and makes an individual more vulnerable to the influence of injurious factors, common in the elderly population, such as hypertension, cardiovascular disease, diabetes, and drugs nephrotoxicity \[[@CR1], [@CR2]\]. The complexity of the background as well as clinical and morphological manifestations of kidney injury impede precise disease recognition, make it difficult to establish prognosis, and hinder proper treatment selection. In a vast majority of cases renal biopsy is irreplaceable in identifying treatable, reversible lesions, as well as in defining both the activity and chronicity of kidney injury. It has been documented that the percentage of patients with the precise kidney disease recognition decreases with age and most of patients aged ≥55 are labelled as 'CKD of unknown origin' or 'nephroangiosclerosis' \[[@CR3]\]. Many nephrologists no longer consider older age as a contraindication to immunosuppressive treatment, which is in line with the growing number of kidney biopsies performed in elderly patients \[[@CR4]\].

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This is a quantitative, descriptive and cross-sectional study that included a group of 2566 adult patients with kidney biopsies that were considered diagnostic (i.e., containing sufficient amount of renal cortex for light microscopic and immunomorphological evaluation as well as ultrastructural study whenever necessary for establishing the diagnosis), and were processed and interpreted over the period of 2009--2014 in the Nephropathological Laboratory, Department of Transplantology, Nephrology and Internal Medicine at Medical University of Warsaw. Among patients studied we identified 352 elderly individuals (accepting an defining age of ≥65 \[[@CR5]\]) as well as a control group of 2214 patients aged 18--64 years. We analyzed kidney-biopsy based diagnoses in terms of their prevalence and clinicopathological associations in both cohorts. The list of clinical data subjected to analysis included patients' gender, age, eGFR (MDRD), a pre-biopsy follow-up duration, the presence of diabetes, hypertension, and urinalysis results. The clinical categories of renal disease at the time of biopsy were defined as follows: nephrotic range proteinuria (≥3.5 g/day) with or without hematuria, non-nephrotic proteinuria (\<3.5 g/day) with or without hematuria, isolated hematuria.

To base our study on most credible and objective measurements, all presumptive and interpretative data, such as those relating to the acuteness/chronicity as well as dynamics of kidney disease evolution, were excluded from the analysis. As the definition of Acute Kidney Injury (AKI) has been changing over the last several years and we were not able to verify the historical data, we didn't include this clinical course characteristic in our analysis.

Pathologic diagnoses {#Sec4}
--------------------

In all cases light microscopic (LM) evaluation and immunofluorescence (IFL) (for IgG, IgA, IgM, C3, C1q, fibrinogen, kappa and lambda lights chains) were performed. The diagnosis of immune-complex mediated glomerulopathies, such as IgAN, MGN, LN, etc. was based on the IFL and LM findings. In 44.8% of biopsies an examination in electron microscopy was also done, which was decided whenever the final diagnosis could not have been made without it. Most commonly the ultrastructural analysis was performed due to: 1) an unspecific/incoherent LM and/or IFL findings; 2) a suspicion of different nephropathies overlap (e.g., DKD coexisting with immune-complex mediated glomerulonephritis); 3) a discrepancy between clinical patients' characteristics and morphological findings in LM and IFL; and 4) a suspected paraproteinemia. The list of morphological diagnoses is presented in Additional file [1](#MOESM1){ref-type="media"}: Table S1. We decided not to use the distinction between primary and secondary nephropathies assuming that at least some cases considered primary at the time of biopsy might have later changed their category once a detailed diagnostic process was completed.

Statistical analyses {#Sec5}
--------------------

The statistical analysis was performed using SAS 9.4 software for Windows. Quantitative variables were summarized by medians (ranges), because the parameters did not follow a normal distribution and they were compared using Wilcoxon Rank-Sum test. Qualitative variables were compared using the *χ*2-test and Fisher's exact test, respectively to the sample size. A *P*-value of \<0.05 was considered statistically significant.

Results {#Sec6}
=======

Baseline characteristics are presented in Table [1](#Tab1){ref-type="table"}. The spectrum of renal biopsy diagnoses in elderly and younger patients is shown in Table [2](#Tab2){ref-type="table"}. Three leading renal biopsy diagnoses among elderly patients were MGN, FSGS, and amyloidosis, whereas in younger individuals IgAN, FSGS and MGN were most frequent ones. In comparison to younger patients the elderly cohort was characterized by higher prevalence of MGN, amyloidosis, *pauci immune* GN, crescentic GN, tubulointerstitial inflammation, and light chain/heavy chain deposition disease (LCDD/HCDD) as well as lower prevalence of IgAN, lupus nephritis (LN) and thin basement membrane disease (TBMD). The pre-biopsy follow-up data (Additional file [2](#MOESM2){ref-type="media"}: Table S2) have been used to define patients' age at the disease onset, and in the frequency analysis of selected nephropathies. Figure [1a](#Fig1){ref-type="fig"} illustrates the frequency of selected nephropathies at different age-groups, whereas Fig. [1b](#Fig1){ref-type="fig"} demonstrates their frequencies in relation to all nephropathies (renal biopsy based diagnoses) occurring in a particular age group.Table 1Clinical characteristics at the time of biopsy by ageElderly (aged ≥65) (*n* = 352)Younger (aged 18--64) (*n* = 2214)*P*Male/female ratio1:11.1/1Age of disease onsetmedian: 69 (range: 19--87)median: 37 (range: 1--64)\<0.001Pre-biopsy follow-up (months)median: 5 (range: 0--660)median: 10 (range: 0--612)\<0.001Pre-biopsy follow-up \<3 months\
 \> 3 months165 (46.9%)\
187 (53.1%)848 (38.3%)\
1366 (61.7%)0.002Proteinuria nephrotic\
 non-nephrotic188 (55.6%)\
134 (39.6%)916 (42.8%)\
1124 (52.5%)\<0.001Hematuria159 (45.3%)1359 (61.8%)\<0.001Nephrotic range proteinuria without hematuria115 (34.2%)453 (21.3%)\<0.001Non-nephrotic proteinuria with hematuria76 (22.5%)787 (37%)Nephrotic range proteinuria with hematuria73 (21.6%)461 (21.6%)Non-nephrotic proteinuria without hematuria58 (17.2%)328 (15.4%)Isolated hematuria8 (2.4%)72 (3.4%)eGFR mL/min/1.73 m^2^median 39.3 (range 2.5--161.6)median 66.8 (range 2.7--252)\<0.001eGFR ≥ 60 mL/min/1.73 m^2^92 (26.1%)1194 (53.9%)\<0.001eGFR 30--59 mL/min/1.73 m^2^113 (32.1%)548 (24.8%)eGFR 15--29 mL/min/1.73 m^2^73 (20.7%)238 (10.8%)eGFR \< 15 mL/min/1.73 m^2^74 (21%)234 (10.5%)Duration of symptoms \< 3 months165 (46.9%)847 (38.3%)0.002Duration of symptoms ≥3 months187 (53.1%)1367 (61.7%)Hypertension287 (84.2%)1398 (67.1%)\<0.001Diabetes64 (18.5%)160 (7.5%)\<0.001Steroid treatment before the biopsy59 (17.5%)491 (23.7%)0.012Other immunosuppressive treatment during pre-biopsy follow-up16 (4.8%)187 (9.0%)0.008 Table 2Renal biopsy diagnoses by ageDiagnosisElderly (aged ≥65) (*n* = 352)Younger (aged 18--64) (*n* = 2214)*P*MGN64 (18.2%)227 (10.3%)\<0.001FSGS61 (17.3%)339 (15.3%)0.342Amyloidosis\
 AL\
 AA\
 Non AA, non AL /not defined49 (13.9%)\
10 (2.8%)\
25 (7.1%)\
14 (4%)82 (3.7%)\
24 (1.1%)\
39 (1.8%)\
19 (0.8%)\<0.001\
0.019\
\<0.001\
\<0.001*Pauci immune* GN\
 crescentic GN\
 focal segmental GN45 (12.8%)\
26 (7.4%)\
19 (5.4%)150 (6.8%)\
82 (3.7%)\
68 (3%)\<0.001\
0.004\
0.037IgAN33 (9.4%)604 (27.3%)\<0.001Crescentic GN (types I,II,III)31 (8.8%)109 (4.9%)0.005MCD22 (6.3%)132 (6%)0.809DKD16 (4.6%)62 (2.9%)0.100Unclassified lesions14 (4%)92 (4.2%)1.000Tubulointerstitial nephritis9 (2.6%)34 (1.5%)0.177Membrano-proliferative GN8 (2.3%)67 (3%)0.608Arterionephrosclerosis (hypertensive nephropathy and aging nephropathy)6 (1.7%)18 (0.8%)0.128MGA6 (1.7%)79 (3.6%)0.077End-stage kidney6 (1.7%)39 (1.8%)1.000LN5 (1.4%)191 (8.6%)\<0.001LCDD/HCDD4 (1.1%)6 (0.3%)0.037Acute tubular injury/necrosis4 (1.1%)8 (0.4%)0.070Thrombotic microangiopathy3 (0.9%)39 (1.8%)0.263Normal kidney morphology2 (0.6%)29 (1.3%)0.303TBMD1 (0.3%)40 (1.8%)0.036The table encompasses only the diagnoses which were made in at least 1% of individuals in any of the two cohorts studied Fig. 1Frequency (**a**) and relative frequency (**b**) distribution of selected kidney biopsy based diagnoses according to age of disease onset

Clinical manifestation of kidney disease in elderly and younger patients {#Sec7}
------------------------------------------------------------------------

A majority among elderly patients presented nephrotic range proteinuria (55.6%) in contrast to younger cohort in which non-nephrotic proteinuria dominated (52.5%, *P* \< 0.001) (Table [1](#Tab1){ref-type="table"}). Among elderly patients with nephrotic range proteinuria the leading diagnoses were MGN (25%), amyloidosis (20.2%) and FSGS (20.2%) in contrast to younger cohort with this clinical syndrome, in which most prevalent were FSGS (17.5%), MGN (16.9%) and IgAN (16.8%). Among elderly patients, a majority of those with nephrotic range proteinuria had no hematuria, and this clinical presentation was most commonly associated with amyloidosis (25.2%) (Table [3](#Tab3){ref-type="table"}).Table 3Distribution of renal biopsy diagnoses among elderly and younger adult patients with nephrotic range proteinuriaNephrotic range proteinuria with hematuria*P*Nephrotic range proteinuria without hematuria*P*Nephrotic range proteinuria with or without hematuria*P*Renal pathology≥65 (*n* = 73)18--64 (*n* = 461)≥65 (*n* = 115)18--64 (*n* = 453)≥65 (*n* = 188)18--64 (*n* = 916)MGN22 (30.1%)49 (10.6%)\<0.00125 (21.7%)106 (23.4%)0.80447 (25.0%)155 (16.9%)0.013FSGS15 (20.6%)79 (17.1%)0.50823 (20.0%)81 (17.9%)0.59138 (20.2%)160 (17.5%)0.404Amyloidosis9 (12.3%)13 (2.8%)0.00129 (25.2%)44 (9.7%)\<0.00138 (20.2%)57 (6.2%)\<0.001*Pauci immune* GN\
crescentic GN\
focal segmental GN7 (9.6%)\
3 (4.1%)\
4 (5.5%)31 (6.7%)\
18 (3.9%)\
13 (2.8)0.336\
1.000\
0.2713 (2.6%)\
1 (0.9%)\
2 (1.7%)4 (0.9%)\
2 (0.4%)\
2 (0.4%)0.151\
0.493\
0.18410 (5.3%)\
4 (2.1%)\
6 (3.2%)35 (3.8%)\
20 (2.2%)\
15 (1.6%)0.317\
1.000\
0.151IgAN6 (8.2%)114 (24.7%)0.0014 (3.5%)39 (8.6%)0.07510 (5.3%)154 (16.8%)\<0.001MCD5 (6.9%)30 (6.5%)0.80411 (9.6%)84 (18.5%)0.02516 (8.5%)114 (12.5%)0.137Membrano-proliferative GN5 (6.9%)30 (6.5%)0.8041 (0.9%)11 (2.4%)0.4756 (3.2%)41 (4.5%)0.553DKD2 (2.7%)26 (5.6%)0.40513 (11.3%)23 (5.1%)0.02915 (8.0%)49 (5.4%)0.170LN1 (1.4%)51 (11.1%)0.005023 (5.1%)0.0071 (0.5%)74 (8.1%)\<0.001End-stage kidney1 (1.4%)4 (0.9%)0.5221 (0.9%)8 (1.8%)0.6952 (1.1%)12 (1.3%)1.000Arterionephrosclerosis1 (1.4%)2 (0.4%)0.3571 (0.9%)5 (1.1%)1.0002 (1.1%)7 (0.8%)0.655MGA03 (0.7%)1.0001 (0.9%)11 (2.4%)0.4751 (0.5%)15 (1.6%)0.498Thrombotic microangiopathy09 (2.0%)0.6181 (0.9%)6 (1.3%)1.0001 (0.5%)15 (1.6%)0.498Unclassified lesions013 (2.8%)0.2323 (2.6%)14 (3.1%)1.0003 (1.6%)27 (3.0%)0.458

Among elderly patients with non-nephrotic range proteinuria the most common diagnoses were *pauci immune* GN (21.6%), FSGS (17.2%) and IgAN (14.9%), whereas in individuals aged 18--64 years with this clinical syndrome IgAN (36.7%), FSGS (14.5%) and LN (9.1%) were most prevalent ones (Table [4](#Tab4){ref-type="table"}).Table 4Distribution of renal biopsy diagnoses among elderly and younger patients with non-nephrotic range proteinuriaNon-nephrotic range proteinuria with hematuria*P*Non-nephrotic range proteinuria without hematuria*P*Non-nephrotic range proteinuria with or without hematuria*P*Renal pathology≥65\
(*n* = 76)18--64 (*n* = 787)≥65\
(*n* = 58)18--64 (*n* = 328)≥65\
(*n* = 134)18--64 (*n* = 1124)*Pauci immune* GN\
 crescentic GN\
 focal segmental GN25 (32.9%)\
15 (19.7%)\
10 (13.2%)92 (11.7%)\
52 (6.6%)\
40 (5.1%)\<0.001\
\<0.001\
0.0094 (6.9%)\
2 (3.5%)\
2 (3.5%)7 (2.1%)\
2 (0.6%)\
5 (1.5%)0.067\
0.109\
0.28429 (21.6%)\
17 (12.7%)\
12 (9.0%)99 (8.8%)\
54 (4.8%)\
45 (4.0%)\<0.001\
0.001\
0.015IgAN15 (19.7%)336 (42.7%)\<0.0015 (8.6%)74 (22.6%)0.01320 (14.9%)413 (36.7%)\<0.001FSGS11 (14.5%)97 (12.3%)0.58612 (20.7%)65 (19.8%)0.86023 (17.2%)163 (14.5%)0.439Unclassified lesions7 (9.2%)29 (3.7%)0.0323 (5.2%)24 (7.3%)0.78110 (7.5%)53 (4.7%)0.204MGN4 (5.3%)27 (3.4%)0.34210 (17.2%)40 (12.2%)0.29214 (10.5%)67 (6.0%)0.046LN2 (2.6%)73 (9.3%)0.0492 (3.5%)28 (8.5%)0.2854 (3.0%)102 (9.1%)0.013Tubulointerstitial nephritis2 (2.6%)4 (0.5%)0.0914 (6.9%)10 (3.1%)0.2426 (4.5%)16 (1.4%)0.023LCDD/HCDD2 (2.6%)2 (0.3%)0.0411 (1.7%)1 (0.3%)0.2783 (2.2%)3 (0.3%)0.019Membrano-proliferative GN2 (2.6%)15 (1.9%)0.65609 (2.7%)0.3662 (1.5%)24 (2.1%)1.000End-stage kidney2 (2.6%)18 (2.3%)0.6942 (3.5%)7 (2.1%)0.6304 (3%)25 (2.2%)0.540TBMD1 (1.3%)23 (2.9%)0.71502 (0.6%)1.0001 (0.8%)25 (2.2%)0.513MCD1 (1.3%)5 (0.6%)0.4264 (6.9%)8 (2.4%)0.0895 (3.7%)13 (1.2%)0.035Amyloidosis1 (1.3%)7 (0.9%)0.5238 (13.8%)15 (4.6%)0.0139 (6.7%)23 (2.1%)0.005MGA031 (3.9%)0.1021 (1.7%)16 (4.9%)0.2811 (0.8%)48 (4.3%)0.046DKD08 (1.0%)1.0001 (1.7%)5 (1.5%)1.0001 (0.8%)13 (1.2%)1.000Thrombotic microangiopathy010 (1.3%)1.0001 (1.7%)9 (2.7%)1.0001 (0.8%)20 (1.8%)0.718Arterionephrosclerosis02 (0.3%)1.0002 (3.5%)6 (1.8%)0.3442 (1.5%)8 (0.7%)0.289Normal kidney morphology012 (1.5%)0.61402 (0.6%)1.000014 (1.3%)0.385Alport syndrome08 (1.0%)1.00002 (0.6%)1.000010 (0.9%)1.000

An isolated hematuria was seen in only 2.4% of elderly patients studied, and was most commonly associated with nonspecific lesions best defined as 'minor glomerular abnormalities' (MGA). In younger individuals an isolated hematuria was a presenting symptom in only 3.4% of patients aged \<65, and was most commonly associated with IgA-N (23.6%), MGA (18.1%), and TBMD (14.0%).

Renal biopsy diagnoses according to gender in the elderly {#Sec8}
---------------------------------------------------------

Significant discrepancies between sexes were found in the frequency of amyloidosis AA, more commonly seen in females (10.8% vs. 3.4%, *P* = 0.011) and IgA-N, significantly more frequently recognized in males (13.1% vs. 5.7%, *P* = 0.027).

Types of kidney disease in elderly diabetic individuals {#Sec9}
-------------------------------------------------------

Among patients aged ≥65 there were 64 (18.2%) individuals with diabetes. The median time of diabetes duration at the time of kidney biopsy was 7.16 years (range 0--24 years). In 11 (17%) of these patients kidney biopsy revealed lesions consistent with pure DKD, in 4 (6%) patients there were morphological features of DKD coexisting with another type of kidney injury, and in 48 (75%) elderly diabetic patients there were no microscopic features of DKD (Table [5](#Tab5){ref-type="table"}). Among elderly patients with diabetes and no DKD on kidney biopsy the most prevalent type of kidney disease was *pauci immune* GN (focal segmental and crescentic) associated with the presence of ANCA.Table 5Renal biopsy diagnoses among patients with diabetesPatients with diabetesKidney biopsy diagnosisDiabetic kidney disease absentDiabetic kidney disease presentCoincidence of diabetic kidney disease and other nephropathy*P*≥ 65 (*n* = 64)48 (75.0%)11 (17.0%)4 (6.0%)^a^0.61218--64 (*n* = 160)98 (61.3%)52 (32.5%)10 (6.3%)^ba^2 cases of MGN, 1case of MCD and 1 case of IgAN^b^6 cases of IgA-N, 1 case of LCDD, 1case of MCD, 2 cases of MGN

Discussion {#Sec10}
==========

CKD, together with diabetes and cardiovascular disease constitute three interrelated conditions of strong public health relevance \[[@CR6]\]. Reduced estimated eGFR is one of the very important risk factors of cardiovascular disease and death \[[@CR7]\]. In US about 30--40% of adults aged ≥70, and approximately 50% of those aged ≥80 have CKD \[[@CR8], [@CR9]\]. In Poland the prevalence of CKD in the elderly population has been recently estimated at 29.4% \[[@CR10]\]. In the elderly CKD exerts stronger effect on the life expectancy than in younger population \[[@CR11]\]. Therefore, early detection of kidney disease, its type recognition, and the implementation of targeted treatment should be regarded as tools necessary to limit CKD complications and to improve outcomes in cardiovascular diseases.

The complexity of renal injury among elderly individuals obscures the clinical picture. Without a renal biopsy the establishment of the proper diagnosis may be impossible, or at least protracted \[[@CR12]--[@CR14]\].

There are no strict criteria qualifying patients to kidney biopsy in any age group. As it has been defined by Bomback et al., kidney biopsy should in general be considered in any patient who presents at least 2 of the following findings: hematuria, proteinuria ≥1 g/day, renal insufficiency, and/or positive serologies for systemic diseases with known potential for kidney involvement (e.g., hepatitis B or C virus infection, systemic lupus erythematosus and ANCA seropositivity) \[[@CR15]\]. As it was emphasized, these indications apply to all age-groups, including elderly (aged ≥65) and very elderly (aged ≥80 years) patients. Several studies confirmed that age is not a significant risk factor for biopsy-related complications \[[@CR13], [@CR16], [@CR17]\].

Although kidney biopsy offers the deepest insight into the renal tissue injury, its morphological interpretation may be problematic in the case of significant interference by lesions related to aging, such as global glomerulosclerosis, arteriosclerosis, arteriolar hyalinization, interstitial fibrosis and tubular atrophy. The additional background injury may also be caused by long-lasting hypertension and/or diabetes, as well as several environmental and iatrogenic factors, which are relatively common in the elderly population.

In our elderly patients studied the most common clinical manifestation of renal disease was nephrotic syndrome (55.6%) with or without hematuria (21.6 and 34.2%, respectively) which was consistent with the observations of others \[[@CR14], [@CR16], [@CR18]--[@CR21]\]. There are also reports documenting AKI as a leading indication for native kidney biopsies in the elderly with nephrotic syndrome being the second most common manifestation of renal disease in this patient group \[[@CR14], [@CR22]\]. What seems to be a problem is the difficulty to define the epidemiology of AKI. This is partly due to the fact that the clinical picture of AKI is very heterogeneous, which has been reflected by the existence of various classification systems based on different diagnostic criteria with the most recent one announced by KDIGO in 2012 \[[@CR23]\]. Our study covered the period between 2009 and 2014, the clinical data were provided by different renal centers, and the descriptions of a disease course were not uniform and precise enough to allow for a reliable distinction between AKI, AKI superimposed on CKD and 'pure' CKD.

Although the spectrum of diseases affecting people aged ≥65 is the same as in younger population, there are some distinct differences in the frequency of certain nephropathies between these two age groups. Our observation of the relatively high incidence of MGN among elderly individuals is in line with the reports of others \[[@CR12], [@CR13], [@CR22], [@CR24], [@CR25]\]. Our data indicate that the peak frequency of MGN occurs at the age 55-64 years, and a peak relative frequency at the age of 65--74 years (Fig. [1](#Fig1){ref-type="fig"}). The histological recognition of MGN provides important rationale for the use of immunosuppressive therapy, especially if progressive eGFR lowering is observed.

Focal segmental glomerulosclerosis was recognized as the second most common histological diagnosis in both elderly and younger patients (17.3 and 15.3% respectively). As in our study, an association between FSGS and nephrotic-range proteinuria, as well as no difference in FSGS frequency between patients aged ≥65 and those aged \<65 were observed by others \[[@CR13], [@CR16], [@CR17]\]. In a vast majority of our cases studied morphological and clinical features suggested the secondary nature of glomerular sclerosis, but the etiology of this process was ambiguous. Although in many elderly patients a contribution of aging, hypertension and arteriosclerosis to the FSGS development could not be excluded, the histological picture was not specific enough to justify a diagnosis of hypertensive nephropathy or arterionephrosclerosis.

In a few published studies that analyzed the prevalence of kidney biopsy based diagnoses in elderly individuals the percentage of cases, in which age and/or hypertension related lesions were dominant microscopic finding ranged from 1.6% in Chinese patients to 6.2% in Japanese cohort \[[@CR19], [@CR24], [@CR26]\]. The proportion of aforementioned diagnosis in our elderly group was 1.7% (Table [2](#Tab2){ref-type="table"}), despite the fact that as much as 84.2% of patients aged ≥65 suffered from hypertension (Table [1](#Tab1){ref-type="table"}.)

Amyloidosis was found to be the third most common histological diagnosis in our elderly patients with a prevalence of 13.9% as compared with 3.7% in younger individuals (*P* \< 0.001). These findings are in line with the reports of others \[[@CR13], [@CR17], [@CR20]\]. Our data show the peak frequency of amyloidosis at the age of 55--64, whereas the highest relative frequency of this disease occurred at the age of 65--74 (Fig. [1](#Fig1){ref-type="fig"}). Amyloidosis was found to be the leading (25.2%) histological finding among elderly patients with nephrotic range proteinuria without hematuria (Table [3](#Tab3){ref-type="table"}.). Although a nephrotic-range proteinuria without hematuria was the most common presentation of amyloidosis in the elderly (61.7%), in a substantial percentage of cases (19%) the disease was manifested by non-nephrotic proteinuria. The latter finding should be emphasized, since many nephrologists refrain from kidney biopsy in an elderly patient with mild proteinuria, in whom concomitant amyloidosis-related cardiomyopathy can be easily misinterpreted as an ischemic heart disease.

Several authors reported the proportion of diabetic kidney disease ranging between 2.2% up to 10% in renal biopsy registries \[[@CR19], [@CR24]\]. The results of ours implicate that in people aged ≥65 DKD constitutes 4.6% of all renal-biopsy diagnoses. In our cohort the peak frequency and the highest relative frequency of this disease occurred at the age of 55--64 years (Fig. [1](#Fig1){ref-type="fig"}). The usual indications for renal biopsy in diabetic patients include: an abrupt onset or rapid progression of kidney disease, the presence of active urinary sediment, and the progression of proteinuria in the absence of diabetic retinopathy or neuropathy. Since the group of diabetic patients in our cohort is not representative for the whole population of diabetics, it should be noted that 75% of our elderly diabetic patients had non-diabetic kidney disease upon kidney biopsy, which is in line with the observation made by Sharma et al. \[[@CR27]\]. These results may be partially explained by the relatively short duration of diabetes at the time of kidney biopsy in our patients (median 7.16 years for diabetic patients studied, range 0--24 years), as well as by the fact that in 40% of biopsies from diabetic individuals electron microscopy was not performed, which does not allow for the exclusion of early phase of DKD.

One of the leading histological diagnoses in general, and the most common renal disease manifested by non-nephrotic range proteinuria with hematuria in our elderly patients was *pauci-immune* GN. Notably, 23.8% of elderly and 24.8% of younger patients with *pauci-immune* GN suffered from nephrotic-range proteinuria. *Pauci-immune* GN being one of the leading diagnoses made upon kidney biopsy among elderly individuals was reported by others \[[@CR13], [@CR25], [@CR28], [@CR29]\]. The peak frequency and the highest relative frequency of this disease in our patients studied occurred at the age of 55-64 years (Fig. [1](#Fig1){ref-type="fig"}). In a vast majority of cases *pauci immune* GN is associated with the presence of ANCA vasculitis, with peak incidence of 52.9 per million being observed among people aged 65--74 \[[@CR30]\]. It is worth mentioning that in contrast to younger individuals, in the elderly vasculitis more commonly manifests with renal disease, and less frequently involves upper respiratory tract \[[@CR29]\]. Vasculitis-related symptoms such as myalgia and headache may be easily misdiagnosed as common afflictions of the elderly, e.g., polymyalgia rheumatica \[[@CR31]\].

Conclusions {#Sec11}
===========

Our analysis confirmed differences in the prevalence of certain kidney diseases between elderly and younger individuals. Elderly patients were more frequently nephrotic, hypertensive and diabetic, and have lower eGFR at the time of the biopsy than younger individuals. A leading clinical manifestation in patients aged ≥65 years submitted to kidney biopsy was proteinuria, most commonly of nephrotic range, which in majority of cases was related to glomerulopathies, Hypertension and age-related lesions rarely were found an exclusive or dominant finding in a kidney biopsy or a cause of proteinuria in individuals aged ≥65 years. The relatively high prevalence of potentially curative kidney diseases in the elderly individuals implicates the importance of renal biopsy in these patients.
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AKI

:   Acute kidney injury

CKD

:   Chronic kidney disease

DKD

:   Diabetic kidney disease

FSGS

:   Focal segmental glomerulosclerosis

GN

:   Glomerulonephritis

IFL

:   Immunofluorescence

IgAN

:   IgA nephropathy

LCDD/HCDD

:   Light and/or heavy chain deposition disease

LM

:   Light microscopy

LN

:   Lupus nephritis

MCD

:   Minimal change disease

MGA

:   Minor glomerular abnormalities

MGN

:   Membranous glomerulonephritis

TBMD

:   Thin basement membrane disease
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